Form 4: Chromocell Therapeutics Director Acquires Restricted Stock Units
SEC Form 4
Todd C. Davis, a director at Chromocell Therapeutics, was granted 49,605 restricted stock units on November 13, 2024, at an exercise price of $0.64 per share.
Summary
- Todd C. Davis, a director of Chromocell Therapeutics, received 49,605 restricted stock units on November 13, 2024.
- These restricted stock units have an exercise price of $0.64 per share.
- The units will vest quarterly over a period of six quarters.
- Following this transaction, Mr. Davis directly owns 263,306 shares of common stock.
Sentiment
Score: 7
Explanation: The document reflects a standard practice of granting equity to a director, which is generally viewed positively as it aligns interests. There are no negative implications.
Positives
- The grant of restricted stock units aligns the director's interests with the company's performance.
- The vesting schedule encourages long-term commitment from the director.
Future Outlook
The restricted stock units will vest over the next six quarters, potentially increasing the director's ownership stake.
Industry Context
The granting of restricted stock units to directors is a common practice to incentivize and align their interests with the company's long-term success.
Comparison to Industry Standards
- Granting restricted stock units to directors is a standard practice across the industry, similar to companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals, which use equity-based compensation to align director interests with shareholder value.
- The vesting schedule of six quarters is also typical, ensuring a longer-term commitment from the director, which is comparable to vesting schedules seen in other biotech companies.
Stakeholder Impact
- The grant of restricted stock units may be viewed positively by shareholders as it aligns the director's interests with the company's long-term performance.
Key Dates
| Date | Description |
|---|---|
| 11/13/2024 | Date of the grant of restricted stock units to Todd C. Davis. |
| 11/15/2024 | Date of the signature on the SEC Form 4. |
Keywords
Restricted Stock Units, Stock Options, Director, Chromocell Therapeutics, Equity, Ownership, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.